Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Teva
Daiichi Sankyo
Chinese Patent Office
Medtronic
Fuji
Cerilliant
Merck
Cipla

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022383

« Back to Dashboard

NDA 022383 describes ARCAPTA NEOHALER, which is a drug marketed by Sunovion Pharms Inc and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug. Additional details are available on the ARCAPTA NEOHALER profile page.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Two suppliers are listed for this compound. Additional details are available on the indacaterol maleate profile page.
Summary for 022383
Tradename:ARCAPTA NEOHALER
Applicant:Sunovion Pharms Inc
Ingredient:indacaterol maleate
Patents:5
Pharmacology for NDA: 022383
Mechanism of ActionAdrenergic beta2-Agonists
Suppliers and Packaging for NDA: 022383
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383 NDA Novartis Pharmaceuticals Corporation 0078-0619 N 0078-0619-06
ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383 NDA Novartis Pharmaceuticals Corporation 0078-0619 N 0078-0619-15

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INHALATIONStrengthEQ 75MCG BASE
Approval Date:Jul 1, 2011TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Feb 25, 2025Product Flag?YSubstance Flag?YDelist Request?
Patented Use:THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
Patent:➤ Try a Free TrialPatent Expiration:Jun 2, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
Patent:➤ Try a Free TrialPatent Expiration:Oct 11, 2028Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Merck
AstraZeneca
Covington
Cerilliant
US Department of Justice
McKesson
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.